Energenesis Biomedical Co. Ltd. (6657.TW) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Taiwan

Price
31.40 TWD
Market cap
2.78 bn TWD
P/E (2025)
–
P/S (2025)
362.09
Dividend yield
0.00 %
Net margin
-3,367.24 %
Return on equity (ROE)
-28.83 %
Return on assets (ROA)
-27.23 %

Energenesis Biomedical Co. Ltd. financials

Fiscal year20242025
Revenue7.75 m TWD7.67 m TWD
Gross profit5.69 m TWD5.83 m TWD
Operating income-255.17 m TWD-275.28 m TWD
EBIT-230.87 m TWD-275.28 m TWD
Net income-231.08 m TWD-258.40 m TWD
Diluted EPS – continuing operations-3.01 TWD-2.92 TWD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Energenesis Biomedical Co. Ltd.

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control. The company also offers scientific products, including western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions. Energenesis Biomedical CO.,LTD. was founded in 2012 and is based in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.